Therapeutic response to ursodeoxycholic acid in cuban patients with primary biliary cholangitis

Authors

Keywords:

primary biliary cholangitis, cirrhosis, survival, ursodeoxycholic acid.

Abstract

Introduction: Primary biliary cholangitis is a chronic and progressive liver disease. Treatment with ursodeoxycholic acid has extended the life expectancy of these patients.

Objective: To describe the therapeutic response to ursodeoxycholic acid in patients with primary biliary cholangitis.

Methods: Descriptive, longitudinal and ambispective study in patients treated at the Institute of Gastroenterology between September 2003 and January 2020. Clinical, laboratory, histological and therapeutic variables were evaluated. The analysis of the results was performed with the SPSS package.

Results: Forty-five patients were included, with a predominance of female gender (95.6%) and a average age of 54 years. Low levels of aspartate amino transferase (p=0.009 HR=0.98) and alkaline phosphatase (p=0.005, HR=0.99), as well as the presence of overlap syndrome (p=0.046 HR=3.08) were associated with a better response to ursodeoxycholic acid. Less than half of the patients responded to conventional treatment with UDCA (47.7 %), most of the non-responders suffer from liver cirrhosis (68 %). No differences were observed in patient survival according to their response to treatment (p =0.585).

Conclusions: Therapeutic response was effective in less than half of those treated with ursodeoxycholic acid. Liver cirrhosis, overlap syndrome, and elevated aspartate amino transferase and alkaline phosphatase levels were associated with poor therapeutic response.

Downloads

Download data is not yet available.

References

1. Czul F, Levy C. Novel therapies on primary biliary cirrhosis. Clin Liver Dis. 2016; 20(1):113-30. DOI: https://doi.org/10.1016/j.cld.2015.08.006

2. Rodríguez DA, Coronado JJ, Solano GA, Otero W. Colangitis biliar primaria. Parte 2. Actualización: diagnóstico, enfermedades asociadas, tratamiento y pronóstico. Rev de Gastro Perú. 2018 [acceso 17/12/21]; 38(1): 64-71. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-51292018000100010&nrm=iso

3. Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and natural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterolo. 2017;8(8):e116. DOI: https://doi.org/10.1038/ctg.2017.43

4. Floreani A, Mangini C. Primary biliary cholangitis: old and novel therapy. Eur J Intern Med. 2018;47:1-5. DOI: https://doi.org/10.1016/j.ejim.2017.06.020

5. European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-72. DOI: https://doi.org/10.1016/j.jhep.2017.03.022

6. Yoo JJ, Cho EJ, Lee B, Kim SG, Kim YS, Lee YB, et al. Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio. Gut Liver. 2018;12(6):714-21. DOI: https://doi.org/10.5009/gnl18271

7. Wilde AB, Lieb C, Leicht E, Greverath LM, Steinhagen LM, Wald de Chamorro N, et al. Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany. J Clin Med. 2021;10(5):1061. DOI: https://doi.org/10.3390/jcm10051061

8. Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2021;27(1):1-21. DOI: https://doi.org/10.3350/cmh.2020.0028

9. Shu Y, Song Y, Bai T, Pan X, Shang H, Yang L, et al. Predictive model of ursodeoxycholic acid treatment response in primary biliary cholangitis. J Clin Transl Hepatol. 2021;9(2):187-93. DOI: https://doi.org/10.14218/jcth.2020.00127

10. Onofrio FQ, Hirschfield GM, Gulamhusein AF. A practical review of primary biliary cholangitis for the Gastroenterologist. Gastroenterol Hepatol. 2019 [acceso 17/12/21];15(3):145-54. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/31061656

11. Murillo CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimen Pharmacol Therapeutics. 2019;50(10):1127-36. DOI: https://doi.org/10.1111/apt.15533

12. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361-7. DOI: https://doi.org/10.1016/j.jhep.2011.02.031

13. Gazda J, Drazilova S, Janicko M, Grgurevic I, Filipec Kanizaj T, Koller T, et al. Prognostic factors in primary biliary cholangitis: a retrospective study of joint slovak and croatian cohort of 249 patients. J Pers Med. 2021;11(6):491 DOI: https://doi.org/10.3390/jpm11060495

14. Chapman RW. Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis. Br J Hosp Med. 2018;79(8):460-4. DOI: https://doi.org/10.12968/hmed.2018.79.8.460

15. Levy C, Naik J, Giordano C, Mandalia A, O'Brien C, Bhamidimarri KR, et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-hispanics. Clin Gastroenterol Hepatol. 2014;12(8):1398-405. DOI: https://doi.org/10.1016/j.cgh.2013.12.010

16. Yerragorla P ND, Shady A, Bergasa NV. Characterization of patients with primary biliary cholangitis and autoimmune hepatitis from a community hospital in East Harlem. Arch Clin Gastroenterol. 2020 [acceso 17/12/21];6(1). Disponible en: https://www.peertechzpublications.com/articles/ACG-6-168.php

17. Gonzalez MS, Delgado LY, Osorio AL, Melendez C. Autoimmune associations in a mexican cohort with primary biliary cholangitis. Rev Gastroenterol Mex. 2019; 84(2):130-5. DOI: https://doi.org/10.1016/j.rgmx.2018.03.008

18. Kaps L, Grambihler A, Yemane B, Nagel M, Labenz C, Ploch P, et al. Symptom burden and treatment response in patients with primary biliary cholangitis (PBC). Dig Dis Sci. 2020;65(10):3006-13. DOI: https://doi.org/10.1007/s10620-019-06009-3

19. Örnolfsson K, Olafsson S, Bergmann O, Lund S, Björnsson E. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population- based study. Scand J Gastroenterol. 2019;54(5):609-16. DOI: https://doi.org/10.1080/00365521.2019.1606931

20. D'Amato D, De Vincentis A, Malinverno F, Vigano M, Alvaro D, Pompili M, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep. 2021;3(2):100248. DOI: https://doi.org/10.1016/j.jhepr.2021.100248

21. Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;3(9):626-34. DOI: https://doi.org/10.1016/s2468-1253(18)30163-8

22. Wetten A, Jones DEJ, Dyson JK. Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough? Expert Opin Pharmacother. 2021;22(15):1949-53. DOI: https://doi.org/10.1080/14656566.2021.1940135

Downloads

Published

2023-01-27

How to Cite

1.
Jiménez Peña FJ, La Rosa Hernández D, Castellanos Fernández MI, Infante Velázquez M, Dorta Guridi Z, Román Martínez Y. Therapeutic response to ursodeoxycholic acid in cuban patients with primary biliary cholangitis. Rev Cubana Inv Bioméd [Internet]. 2023 Jan. 27 [cited 2025 Sep. 18];42(1). Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/2433

Issue

Vol. 42 (2023)

Section

ARTÍCULOS ORIGINALES

License

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).

Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.